share_log

The IPO Market Is On Fire With Another Record Week Ahead

The IPO Market Is On Fire With Another Record Week Ahead

IPO市场火爆,未来一周将再创新高
Benzinga Real-time News ·  2021/07/27 10:46

After another week of record activity, the IPO market will be even hotter with 25 scheduled IPOs this week. If all scheduled IPOs begin trading as expected, this will be the busiest week for the US IPO market in more than two decades.

在经历了又一周的创纪录活动后,IPO市场将更加火爆,本周将有25宗预定IPO。如果所有预定的IPO都像预期的那样开始交易,这将是美国IPO市场20多年来最繁忙的一周。

Vehicle low-voltage battery maker profitable on an EBIT basis, Clarios International (NYSE:BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. After negative revenue growth last year due to the pandemic, revenue growth has accelerated during the first half of 2021.

车辆低压电池制造商在息税前利润的基础上,克拉里奥斯国际(纽约证券交易所:BTRY)计划以97亿美元的市值筹集17亿美元。在去年因疫情而出现收入负增长之后,2021年上半年收入增长加快。

A profitable cloud-based programmatic digital advertising platform that provides monetization services to about 3,100 publishers, Teads (NASDAQ:TEAD) plans to raise $751 million at a $4.6 billion market cap.

Teads是一个盈利的基于云的程序化数字广告平台,为大约3100家出版商提供货币化服务(NASDAQ:Tead)计划以46亿美元的市值筹集7.51亿美元。

Provider of an education platform that enables teachers to manage their virtual classrooms such as collective work and grade assignments, PowerSchool Holdings (NYSE:PWSC) plans to raise $750 million at a $3.7 billion market cap. It served 12,000 customers across 90 countries, becoming profitable on a net income basis during the first half of 2021.

提供一个教育平台,使教师能够管理他们的虚拟教室,如集体作业和成绩作业,PowerSchool控股公司纽约证券交易所代码:PWSC)计划以37亿美元的市值筹集7.5亿美元。它为90个国家的1.2万名客户提供了服务,2021年上半年在净收入的基础上实现了盈利。

After withdrawing from its public debut in 2018, a leading, profitable, and slow-growing fruit and vegetable company offering 300 products sourced from over 30 countries to over 80 countries across the globe, Dole (NYSE:DOLE) plans to raise $559 million this time around, at a $2 billion market cap.

在2018年退出公开上市后,一家领先的、盈利的、增长缓慢的水果和蔬菜公司提供了300种产品,这些产品来自30多个国家,销往全球80多个国家。失业救济金纽约证券交易所代码:失业救济金)计划这一次筹资5.59亿美元,市值20亿美元。

Language learning platform that educated over 300 million users, Duolingo (NASDAQ:DUOL) plans to raise $460 million at a $4.1 billion market cap. The pandemic fueled triple-digit growth last year.

语言学习平台,教育了超过3亿用户,多林戈(纳斯达克:DUOL)计划以41亿美元的市值筹集4.6亿美元。去年,这场大流行推动了三位数的增长。

Manufacturer of premium grills that can be controlled via an app, Traeger (NYSE:COOK) plans to raise $400 million at a $2.2 billion market cap.

可以通过应用程序控制的高级烧烤架制造商,特雷格纽约证券交易所代码:)计划以22亿美元的市值筹集4亿美元。

Growing but unprofitable Riskified (NYSE:RSKD) provides e-commerce fraud protection for enterprises, plans to raise $333 million on July 29th. FCF was positive over the first quarter of 2021.

增长但无利可图的Riskized(纽约证券交易所:RSKD)为企业提供电商诈骗保护,计划7月29日融资3.33亿美元。FCF在2021年第一季度为正。

Financial software provider for mid-market community banks and credit unions, MeridianLink (NYSE:MLNK), plans to raise $300 million at a $2.1 billion market cap. The nature of its business is cyclical, but strong mortgage activity enabled double-digit organic growth.

面向中端市场社区银行和信用社的金融软件提供商子午线纽约证券交易所代码:MLNK),计划以21亿美元的市值筹集3亿美元。其业务性质是周期性的,但强劲的抵押贷款活动使其实现了两位数的有机增长。

Smart home integration system that demonstrated solid growth and profitability on EBIT basis, Snap One Holdings (NASDAQ:SNPO), plans to raise $270 million at a $1.5 billion market cap.

智能家居集成系统在息税前利润的基础上表现出稳健的增长和盈利能力,Snap One Holdings(纳斯达克:SNPO),计划以15亿美元的市值筹集2.7亿美元。

Specialty funding solutions provider for projects of significant social and economic importance to local communities in the US, Preston Hollow Community Capital (NYSE:PHCC), plans to raise $200 million at a $2.3 billion market cap.

为对美国当地社区具有重大社会和经济意义的项目提供专业融资解决方案,普雷斯顿霍洛社区资本纽约证券交易所代码:PHCC),计划以23亿美元的市值筹集2亿美元。

Oncology biotech Nuvalent (NYSE:NUVL) plans to raise $151 million at an $835 million market cap. Its lead candidate treats ROS1-positive non-small cell lung cancer and other advanced solid tumors, with trials expected to begin by year-end.

肿瘤学生物技术核价纽约证券交易所代码:NUVL)计划以8.35亿美元的市值筹集1.51亿美元。它的主要候选药物是治疗ROS1阳性的非小细胞肺癌和其他晚期实体肿瘤,预计试验将于年底开始。

AIM-listed cell engineering platform MaxCyte (NASDAQ:MXCT) plans to raise $150 million at a $1.3 billion market cap. Its flagship product can be used across the rapidly expanding cell therapy sector.

在AIM上市的细胞工程平台MaxCyte(纳斯达克:MXCT)计划以13亿美元的市值筹集1.5亿美元。其旗舰产品可用于快速扩张的细胞治疗领域。

A clinical stage vaccine biotech Icosavax (NASDAQ:ICVX) plans to raise $150 million at a $590 million market cap. This biotech is focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology, with its most advanced candidate aimed at SARS-CoV-2 currently in a Phase 1/2 trial.

一种临床阶段疫苗生物技术Icosavax(纳斯达克:ICVX)计划以5.9亿美元的市值筹集1.5亿美元。这项生物技术专注于利用其类似病毒的颗粒平台技术开发针对传染性呼吸道疾病的疫苗,其最先进的候选疫苗针对SARS-CoV-2目前处于1/2阶段试验。

Genetic and non-genetic heart disease biotech Tenaya Therapeutics (NASDAQ:TNYA) plans to raise $150 million at a $585 million market cap. It has three programs: gene therapy, cellular regeneration, and precision medicine. INDs submission is planned for 2022.

遗传性和非遗传性心脏病生物技术天谷治疗公司(Tenaya Treateutics)(纳斯达克:TNYA)计划以5.85亿美元的市值筹集1.5亿美元。它有三个项目:基因治疗、细胞再生和精确医学。INDS提交计划于2022年提交。

Gene therapy biotech in preclinical stage spanning across regenerative medicine and multigenic diseases, Omega Therapeutics (NASDAQ:OMGA) plans to raise $126 million at an $866 million market cap.

横跨再生医学和多基因疾病的临床前阶段的基因治疗生物技术,欧米茄治疗公司(NASDAQ:OMGA)计划以8.66亿美元的市值筹集1.26亿美元。

RxSight (NASDAQ:RXST) is developing the first and only commercially available intraocular lens technology to enables doctors to customize and optimize visual acuity after a patient undergoes cataract surgery. It plans to raise $125 million, aiming for a $477 million market cap.

RxSight(纳斯达克:RXST)正在开发第一项也是唯一一项商业化的人工晶状体技术,使医生能够在患者接受白内障手术后定制和优化视力。它计划筹集1.25亿美元,目标是市值达到4.77亿美元。

Oncology biotech Immuneering (NASDAQ:IMRX) plans to raise $105 million at a $391 million market cap. Its flagship program is aimed to treat advanced solid tumor patients harboring RAS mutant tumors. The company plans to submit its first IND next year and anticipates filings at least two additional INDs in 2023 and 2024.

肿瘤学生物技术免疫接种(纳斯达克:IMRX)计划以3.91亿美元的市值筹集1.05亿美元。其旗舰计划旨在治疗携带RAS突变肿瘤的晚期实体肿瘤患者。该公司计划明年提交第一份IND,预计在2023年和2024年至少再提交两份IND申请。

Rani Therapeutics  (NASDAQ:RANI) aims to replace subcutaneous or IV injections with oral dosing plans to raise $100 million at a $724 million market cap. The RaniPill capsule is a novel, proprietary, and patented platform technology.

拉尼治疗公司(纳斯达克:拉尼)旨在用口服剂量计划取代皮下或静脉注射,以7.24亿美元的市值筹集1亿美元。RaniPill胶囊是一种新颖的、专有的、获得专利的平台技术。

A biotech focused on treating cancer, Candel Therapeutics (NASDAQ:CADL) hopes to raise $85 million. Its most advanced candidate is currently in a Phase 3 trial for newly diagnosed localized prostate cancer with an intermediate or high risk for progression.

一种专注于治疗癌症的生物技术,秋茄治疗公司(纳斯达克:CADL)希望筹集8500万美元。它最先进的候选药物目前正处于新诊断的中高进展风险的局部性前列腺癌的3期试验中。

Rare disease clinical-stage biotech Rallybio (NASDAQ:RLYB) plans to raise $81 million at a $465 million market cap. Its lead program aimed to treat fetal and neonatal alloimmune thrombocytopenia is currently in Phase 1/2 trial.

罕见疾病临床期生物技术Rallybio(纳斯达克:RLYB)计划以4.65亿美元的市值筹集8100万美元。它的主要项目旨在治疗胎儿和新生儿同种异体免疫性血小板减少症,目前正处于1/2期试验。

Ocean Biomedical (NASDAQ:OCEA) is pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed from Brown University, Stanford University, and Rhode Island Hospital aims to raise $50 million.

海洋生物医学(纳斯达克:屋宇)正在开展肿瘤学、纤维化、传染病和炎症等临床前项目,这些项目已获得布朗大学、斯坦福大学和罗德岛医院的许可,计划筹集5000万美元。

After postponing its public debut last November, IN8bio (NASDAQ:INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing cell therapies to treat solid tumors.

在去年11月推迟公开亮相后,IN8Bio(纳斯达克:INAB)计划以2.15亿美元的市值筹集4400万美元。这一阶段的生物技术正在开发治疗实体肿瘤的细胞疗法。

A profitable Chinese organic fertilizer producer Muliang Viagoo (NASDAQ:MULG) is aiming for a market cap of $194 million, hoping to raise $40 million.

一家盈利的中国有机肥生产商木良伟哥(纳斯达克:MULG)的目标是市值1.94亿美元,希望筹集4,000万美元。

Biotech aimed at curing female cancer, Context Therapeutics (NASDAQ:CNTX) plans to raise $20 million at a $93 million market cap. Its lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer.

旨在治愈女性癌症的生物技术,情境治疗学(纳斯达克:CNTX)计划以9300万美元的市值筹集2000万美元。它的主要候选药物目前正在卵巢癌和子宫内膜癌的第二阶段试验中。

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you're interested in becoming an IAM journalist contact: contributors@iamnewswire.com

本文不是新闻稿,由IAMNewswire的一位经过验证的独立记者贡献。任何时候都不应将其理解为投资建议,请阅读全文披露。IAM Newswire在上述公司没有任何职位。新闻稿-如果您正在寻找完整的新闻稿分发联系人:电子邮件:press@iamnewswre.com撰稿人-IAM Newswire接受推介。如果您有兴趣成为一名IAM记者,请联系:邮箱:Contributors@iamnewswre.com

Image by Free-Photos from Pixabay

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发